BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer

被引:24
|
作者
Li, Da [1 ]
Chen, Na-Na [2 ]
Cao, Ji-Min [3 ]
Sun, Wu-Ping [4 ]
Zhou, Yi-Ming [4 ]
Li, Chun-Yan [5 ]
Wang, Xiu-Xia [1 ]
机构
[1] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China
[2] Nagoya Univ, Grad Sch Med, Dept Mol Immunol, Nagoya, Aichi 4648601, Japan
[3] Chinese Acad Med Sci, Dept Physiol & Pathophysiol, Inst Basic Med Sci, Peking Union Med Coll,Sch Basic Med, Beijing 100730, Peoples R China
[4] Natl Inst Physiol Sci, Div Cell Signaling, Okazaki, Aichi 444, Japan
[5] Chinese Acad Med Sci, Peking Union Med Coll, Sch Basic Med, Dept Histol & Embryol,Inst Basic Med, Beijing 100730, Peoples R China
关键词
BRCA1; NAD; NADH; Nampt; ovarian cancer; breast cancer type 1 susceptibility protein; CtBP; C-terminal binding proteins; nicotinamide adenine dinucleotide; nicotinamide phosphoribosyltransferase; PCR; polymerase chain reaction; shRNAs; short hairpin ribonucleic acids; TRANSCRIPTIONAL REGULATION; BREAST-CANCER; RECEPTOR; EXPRESSION; IDENTIFICATION; CROSSTALK; CELLS;
D O I
10.4161/15384101.2015.942208
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Both hereditary factors (e.g., BRCA1) and nicotinamide adenine dinucleotide (NAD)-dependent metabolic pathways are implicated in the initiation and progression of ovarian cancer. However, whether crosstalk exists between BRCA1 and NAD metabolism remains largely unknown. Here, we showed that: (i) BRCA1 inactivation events (mutation and promoter methylation) were accompanied by elevated levels of NAD; (ii) the knockdown or overexpression of BRCA1 was an effective way to induce an increase or decrease of nicotinamide phosphoribosyltransferase (Nampt)-related NAD synthesis, respectively; and (iii) BRCA1 expression patterns were inversely correlated with NAD levels in human ovarian cancer specimens. In addition, it is worth noting that: (i) NAD incubation induced increased levels of BRCA1 in a concentration-dependent manner; (ii) Nampt knockdown-mediated reduction in NAD levels was effective at inhibiting BRCA1 expression; and (iii) the overexpression of Nampt led to higher NAD levels and a subsequent increase in BRCA1 levels in primary ovarian cancer cells and A2780, HO-8910 and ES2 ovarian cancer cell lines. These results highlight a novel link between BRCA1 and NAD. Our findings imply that genetic (e.g., BRCA1 inactivation) and NAD-dependent metabolic pathways are jointly involved in the malignant progression of ovarian cancer.
引用
收藏
页码:2564 / 2571
页数:8
相关论文
共 50 条
  • [21] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [22] Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Ramus, Susan J.
    Antoniou, Antonis C.
    Kuchenbaecker, Karoline B.
    Soucy, Penny
    Beesley, Jonathan
    Chen, Xiaoqing
    McGuffog, Lesley
    Sinilnikova, Olga M.
    Healey, Sue
    Barrowdale, Daniel
    Lee, Andrew
    Thomassen, Mads
    HUMAN MUTATION, 2012, 33 (04) : 690 - 702
  • [23] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [24] Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women
    Loizzi, Vera
    Cerbone, Marco
    Arezzo, Francesca
    Silvestris, Erica
    Damiani, Gianluca Raffaello
    Cazzato, Gerardo
    Cicinelli, Ettore
    Cormio, Gennaro
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2024, 23 (02): : 277 - 286
  • [25] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [26] BRCA1 in breast and ovarian cancer predisposition
    Billack, B
    Monteiro, ANA
    CANCER LETTERS, 2005, 227 (01) : 1 - 7
  • [27] BRCA1 mutations in familial ovarian cancer
    Lallas, TA
    Buekers, TE
    Buller, RE
    MOLECULAR GENETICS AND METABOLISM, 1999, 67 (04) : 357 - 363
  • [28] The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Metcalfe, KA
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olivotto, IA
    Foulkes, WD
    Warner, E
    Olopade, O
    Eisen, A
    Weber, B
    McLennan, J
    Sun, P
    Narod, SA
    GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 222 - 226
  • [29] Nicotinamide Adenine Dinucleotide (NAD+) Repletion Attenuates Bupivacaine-Induced Neurotoxicity
    Zheng, Ting
    Xu, Shi Yuan
    Zhou, Shu Qin
    Lai, Lu Ying
    Li, Le
    NEUROCHEMICAL RESEARCH, 2013, 38 (09) : 1880 - 1894
  • [30] Extracellular metabolism of the enteric inhibitory neurotransmitter β-nicotinamide adenine dinucleotide (β-NAD) in the murine colon
    Durnin, Leonie
    Kurahashi, Masaaki
    Sanders, Kenton M.
    Mutafova-Yambolieva, Violeta N.
    JOURNAL OF PHYSIOLOGY-LONDON, 2020, 598 (20): : 4509 - 4521